The pharmaceutical sector has grown by an average annual rate of 8% over the last decade, reaching RM8.6 billion or 16.5% of total healthcare expenditure (RM52 billion) in 2016. Imported medicines at RM5.4 billion still account for the largest part (63%) of the RM8.6 billion pharmaceutical market, while exports are only RM0.7 billion. Generic medicines now account for 55% of the controlled (prescription) medicines market by value.

The market structure of Malaysia’s pharmaceutical sector is characterized by a three-level supply chain, starting with manufacturers of generic medicines and importers of originator and generic medicines at the first level, wholesalers and distributors at the second level, and providers at the third level who provide medicines to patients and end users.

PART ONE: Overview of Malaysia’s Pharmaceutical Sector

Chapter 1: Overall Growth of the Healthcare and Pharmaceutical Sectors 
Chapter 2: Market Structure and Supply Chain 
Chapter 3: Market Share and Market Concentration 
Chapter 4: Market Dominance and Impact on Availability,
Affordability and Accessibility of Medicines

PART TWO: Competition Concerns in the Pharmaceutical Sector

Chapter 5: Key Existing Laws and Regulations and An Assessment of Impacts 
Chapter 6: Competition Concerns Among Industry Players 
Chapter 7: Selected Case Studies on Anti-Competitive Conduct

PART THREE: Conclusion and Recommendations